pSivida breaks BrachySil into Chinese market
This article was originally published in Clinica
Australian bio-nanotech company pSivida has licensed its BrachySil technology to Beijing Med-Pharm for marketing and distribution in the Chinese market. Under the terms of the agreement, pSivida will pay its newly-appointed distributor upfront and milestone payments totalling more than $2m for clinical development of the product and securing regulatory approval, as well as royalties of up to 30% on future sales. The Perth-based company will retain the manufacturing rights to BrachySil.